NO20062561L - Kinoliner nyttige for behandling av kardiovaskulaere sykdommer - Google Patents

Kinoliner nyttige for behandling av kardiovaskulaere sykdommer

Info

Publication number
NO20062561L
NO20062561L NO20062561A NO20062561A NO20062561L NO 20062561 L NO20062561 L NO 20062561L NO 20062561 A NO20062561 A NO 20062561A NO 20062561 A NO20062561 A NO 20062561A NO 20062561 L NO20062561 L NO 20062561L
Authority
NO
Norway
Prior art keywords
treatment
cardiovascular diseases
useful
quinolines useful
quinolines
Prior art date
Application number
NO20062561A
Other languages
English (en)
Norwegian (no)
Inventor
Michael David Collini
Christopher Paul Miller
Robert L Morris
John William Ullrich
Baihua Hu
Merle M Elloso
Ronald Charles Bernotas
Robert R Singhaus Jr
James W Jetter
David H Kaufman
Rayomand J Unwalla
Jay E Wrobel
Elaine Quinet
Ponnal Nambi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34704262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062561(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062561L publication Critical patent/NO20062561L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20062561A 2003-12-12 2006-06-02 Kinoliner nyttige for behandling av kardiovaskulaere sykdommer NO20062561L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52900903P 2003-12-12 2003-12-12
US60029604P 2004-08-10 2004-08-10
PCT/US2004/041399 WO2005058834A2 (fr) 2003-12-12 2004-12-10 Quinolines convenant pour le traitement de maladies cardio-vasculaires

Publications (1)

Publication Number Publication Date
NO20062561L true NO20062561L (no) 2006-09-08

Family

ID=34704262

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062561A NO20062561L (no) 2003-12-12 2006-06-02 Kinoliner nyttige for behandling av kardiovaskulaere sykdommer

Country Status (18)

Country Link
US (1) US7576215B2 (fr)
EP (2) EP2284157A1 (fr)
JP (1) JP2007516258A (fr)
KR (1) KR20070001922A (fr)
AR (1) AR047329A1 (fr)
AU (1) AU2004298486A1 (fr)
BR (1) BRPI0417543A (fr)
CA (1) CA2547518A1 (fr)
CR (1) CR8410A (fr)
EC (1) ECSP066635A (fr)
IL (1) IL175892A0 (fr)
NO (1) NO20062561L (fr)
PA (1) PA8619901A1 (fr)
PE (1) PE20050676A1 (fr)
RU (1) RU2006124843A (fr)
SV (1) SV2005001973A (fr)
TW (1) TW200529845A (fr)
WO (1) WO2005058834A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490047B1 (fr) * 2002-03-27 2009-12-30 SmithKline Beecham Corporation Certains heterocycles aminoalkyles pharmaceutiquement utiles
JP2005521721A (ja) * 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
US7247748B2 (en) * 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
AU2003226094A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
EP2172222A3 (fr) * 2004-04-26 2010-06-23 Ono Pharmaceutical Co., Ltd. Nouvelle maladie à médiation BLT2, agent de liaison BLT2 et composé
US20070299092A1 (en) * 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
JP4936476B2 (ja) 2005-06-28 2012-05-23 第一三共株式会社 Ｌｘｒリガンドの試験方法
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
WO2007050271A2 (fr) * 2005-10-25 2007-05-03 Wyeth Modulateurs de 5-lipoxygenase
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
AU2007297721A1 (en) * 2006-09-19 2008-03-27 Wyeth Use of LXR agonists for the treatment of osteoarthritis
WO2008036238A2 (fr) * 2006-09-19 2008-03-27 Wyeth Utilisation de modulateurs lxr dans la prévention et le traitement du vieillissement cutané
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
EP2099444A4 (fr) * 2006-12-14 2012-11-07 Nps Pharma Inc Utilisation de dérivés de la d-sérine pour le traitement de troubles de l'anxiété
US20090069373A1 (en) * 2007-02-28 2009-03-12 Wyeth Quinoline Acids
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
RU2009137190A (ru) * 2007-03-08 2011-04-20 Плексксикон, Инк. (Us) Соединения, обладающие активностью в отношении ppar
ES2329639B1 (es) * 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
BRPI0812816B8 (pt) * 2007-06-18 2021-05-25 Richter Gedeon Nyrt compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
CA2705318C (fr) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibiteurs de la replication du virus de l'immunodeficience humaine
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
AU2008345696A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
WO2009102789A2 (fr) * 2008-02-15 2009-08-20 Wyeth Utilisation d'agonistes de rxr pour le traitement de l'arthrose
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
WO2009133692A1 (fr) 2008-04-30 2009-11-05 興和株式会社 Composé quinoline
US8153634B2 (en) 2008-05-29 2012-04-10 Kowa Company, Ltd. Carbinol derivatives having cyclic linker
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
RU2514427C2 (ru) * 2008-06-16 2014-04-27 Юниверсити Оф Теннесси Рисёч Фаундейшн Соединения для лечения рака
WO2010012650A1 (fr) * 2008-07-28 2010-02-04 Syddansk Universitet Composés destinés au traitement de troubles métaboliques
JP5281647B2 (ja) * 2008-09-08 2013-09-04 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤
CA2741537A1 (fr) * 2008-11-07 2010-05-14 Wyeth Llc Modulateurs de lxr a base de quinoxaline
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
AU2009322170A1 (en) * 2008-12-05 2011-07-14 Medicines For Malaria Venture Compounds having antiparasitic or anti-infectious activity
KR101671046B1 (ko) 2009-04-29 2016-10-31 코와 가부시키가이샤 헤테로환 링커를 갖는 카르비놀 화합물
CA2759083A1 (fr) 2009-04-30 2010-11-04 Novartis Ag Derives d'imidazole et leur utilisation comme modulateurs des kinases dependantes des cyclines
CA2765819A1 (fr) * 2009-06-25 2010-12-29 Amgen Inc. Composes heterocycliques et leurs utilisations en tant qu'inhibiteurs de l'activite p13 k
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103097355A (zh) * 2010-07-08 2013-05-08 惠氏有限责任公司 用于治疗皮肤病的新的喹啉酯
CN103517908A (zh) 2010-09-07 2014-01-15 Seoul大学校产学协力财团 二倍半萜化合物及其用途
ES2379242B1 (es) * 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromeno.
ES2941477T3 (es) 2012-08-13 2023-05-23 Univ Rockefeller Agonista de LXRbeta para el tratamiento de cáncer
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
BR112015008308A2 (pt) 2012-10-16 2017-12-05 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por metileno do ror-gama-t
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
CN103965105A (zh) * 2013-01-29 2014-08-06 中山大学 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用
WO2014123203A1 (fr) * 2013-02-06 2014-08-14 京都薬品工業株式会社 Agent thérapeutique destiné à traiter le diabète
RU2708247C2 (ru) 2013-03-05 2019-12-05 Юниверсити Оф Теннесси Рисерч Фаундейшн Соединение для лечения рака
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
BR112016008257A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de roryt de álcool quinolínico secundário
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
WO2015106164A1 (fr) 2014-01-10 2015-07-16 Rgenix, Inc. Agonistes du récepteur x du foie et leurs utilisations
CN104036909B (zh) * 2014-06-25 2016-09-28 桂林理工大学 磁性材料[Cu3(N3)6(DMF)2]n及合成方法
WO2016057454A1 (fr) 2014-10-06 2016-04-14 The Johns Hopkins University Ciblage de récepteurs nucléaires de foie comme traitement pour la maladie de wilson
EP3402477A4 (fr) 2016-01-11 2019-08-21 The Rockefeller University Méthodes pour le traitement de troubles associés à des cellules suppressives dérivées de cellules myéloïdes
EP3246028A1 (fr) * 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés de quinoléine pour augmenter la libération d'insuline
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US11084781B2 (en) * 2017-05-12 2021-08-10 Research Triangle Institute Diarylureas as CB1 allosteric modulators
WO2019074241A1 (fr) * 2017-10-11 2019-04-18 정원혁 Inhibiteur de l'interaction entre pd-1 et pd-l1, comprenant un dérivé de phénylacétylène
EP4155300A1 (fr) 2017-10-30 2023-03-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Analogues de quinoléine substitués utilisés en tant qu'inhibiteurs d'aldéhyde déshydrogénase 1a1 (aldh1a1)
WO2019104062A1 (fr) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphes et leurs utilisations
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
US11884647B2 (en) 2019-10-18 2024-01-30 The Regents Of The University Of California Compounds and methods for targeting pathogenic blood vessels
WO2021096589A1 (fr) * 2019-11-15 2021-05-20 Georgia State University Research Foundation, Inc. Inhibiteurs de polymérase à petites molécules
ES2982346T3 (es) 2019-12-13 2024-10-15 Inspirna Inc Sales metálicas y usos de las mismas

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2962658D1 (en) 1978-01-28 1982-06-24 Croda Synthetic Chem Ltd Process for the preparation of aromatic (b)-fused pyridines and novel thieno(b)pyridines
US4407803A (en) 1981-08-17 1983-10-04 Abbott Laboratories Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
DE3413078A1 (de) 1984-04-06 1985-10-24 Miles Laboratories, Inc., Elkhart, Ind. Chromogene aminosaeure- und peptidester, verfahren zu deren herstellung, verwendung dieser verbindungen in analysenverfahren sowie mittel zum nachweis esterolytischer und/oder proteolytischer enzyme
CA1336714C (fr) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Mevalonolactone de type quinoleine utilisee comme inhibiteurs de la biosynthese du cholesterol
US4761419A (en) 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NZ231631A (en) 1988-12-08 1992-07-28 Duphar Int Res Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions
DE3905908A1 (de) 1989-02-25 1990-09-06 Bayer Ag Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
DE3908298A1 (de) 1989-03-14 1990-09-20 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-n,n'-sulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3927369A1 (de) 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
DE3927931A1 (de) 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
DE3927930A1 (de) 1989-08-24 1991-02-28 Bayer Ag Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
DE3935139A1 (de) 1989-10-21 1991-04-25 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-thioharnstoffe
DE3935491A1 (de) 1989-10-25 1991-05-02 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
JPH04182469A (ja) 1990-11-16 1992-06-30 Terumo Corp 新規なチオエステル化合物
JP2696150B2 (ja) 1991-02-05 1998-01-14 株式会社大塚製薬工場 キノリン誘導体
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
DE4139751A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
DE4105551A1 (de) 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4112533A1 (de) 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
EP0590094A1 (fr) * 1991-04-26 1994-04-06 Pfizer Inc. Derives de 4-aryle-3-(heteroarylureido)quinoline
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
DE4128681A1 (de) 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP3130342B2 (ja) 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JPH05128327A (ja) 1991-11-01 1993-05-25 Mitsubishi Electric Corp Ｉｃカード
JPH05130897A (ja) 1991-11-11 1993-05-28 Terumo Corp チオール化合物測定用試薬組成物
DE4139749A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenyl-essigsaeureamide
DE4139750A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5183825A (en) 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
EP0570112A1 (fr) 1992-04-23 1993-11-18 Zeneca Limited Dérivés de cycloalcanes
DE4226519A1 (de) 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
JPH0692939A (ja) 1992-09-16 1994-04-05 Kyowa Hakko Kogyo Co Ltd イミダゾール誘導体
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
ES2114654T3 (es) * 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
JPH0710870A (ja) 1993-06-23 1995-01-13 Asahi Glass Co Ltd 新規アミノピリジン誘導体およびその塩
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
DK0724588T3 (da) * 1993-09-17 2000-05-15 Smithkline Beecham Corp Lægemiddelbindende protein
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
US5453509A (en) 1993-10-08 1995-09-26 Synaptic Pharmaceutical Corporation Functionalization of acyl pyridinium salts
DE4411657A1 (de) 1994-04-02 1995-10-05 Basf Ag Verfahren zur Herstellung von 6-Hydroxymethylchinolinen
FR2722198B1 (fr) 1994-07-08 1996-10-04 Pf Medicament 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE19500120A1 (de) 1995-01-04 1996-07-11 Bayer Ag Neue acylierte Pseudopeptide mit trifluormethyl-subsstituiertem 2-Azabicyclooctan
DE19500122A1 (de) 1995-01-04 1996-07-11 Bayer Ag Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
DE19532714A1 (de) 1995-09-05 1997-03-06 Bayer Ag Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden
JPH1067658A (ja) 1995-09-13 1998-03-10 Takeda Chem Ind Ltd 免疫抑制剤
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
EP0808627A2 (fr) 1996-05-22 1997-11-26 Hoechst Aktiengesellschaft Utilisation des antagonistes de la bradykinine non-peptidiques pour le traitement et la prévention des maladies de foie fibrotiques chroniques, des maladies de foie aigues et complications
JPH101471A (ja) 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
WO1998014430A1 (fr) 1996-10-02 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrimidine
JP2001503756A (ja) 1996-11-06 2001-03-21 ダーウィン・ディスカバリー・リミテッド キノリン類およびこれらの治療的使用
AU8191998A (en) 1997-02-04 1998-08-25 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0991623A2 (fr) 1997-06-19 2000-04-12 Sepracor, Inc. Agents antimicrobiens quinoleine-indole, utilisations et compositions associees
AR016294A1 (es) 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6538022B1 (en) 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
CA2392568A1 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
CA2396865C (fr) 2000-02-04 2009-04-14 Janssen Pharmaceutica N.V. Inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer du sein
ATE375794T1 (de) 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
EP1261348A2 (fr) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
EP1261342A2 (fr) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl-proteine transferase
CA2397253A1 (fr) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
JP2003525255A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
WO2001064199A2 (fr) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl-proteine transferase avec compose a base de taxane
US20030022918A1 (en) 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20030027808A1 (en) 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001070227A1 (fr) 2000-03-17 2001-09-27 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadotropine
AU4742101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2001261654A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6495562B1 (en) 2000-04-25 2002-12-17 Abbott Laboratories Naphthamidine urokinase inhibitors
AU2001262984A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6949656B2 (en) 2000-08-08 2005-09-27 Shionogi & Co., Ltd. Cyclic amine derivatives and use thereof
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US7226945B2 (en) 2000-10-13 2007-06-05 Astrazeneca Ab Estrogen receptor-β ligands
WO2002090375A2 (fr) 2001-05-03 2002-11-14 The University Of Chicago Agonistes du recepteur x hepatique
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
EP1270535A3 (fr) 2001-06-20 2004-02-18 Clariant GmbH Méthode de préparation de composés aromatiques substitués
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
EP2168576A3 (fr) * 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Composés tricycliques dans le traitement de la dyslipidémie et des maladies artériosclérotiques
AU2002336433A1 (en) * 2001-10-08 2003-04-22 Eli Lilly And Company Tricyclic compounds useful for modulating lxr
JP2005533007A (ja) * 2002-03-27 2005-11-04 スミスクライン・ビーチャム・コーポレイション Ｌｘｒ調節因子を用いる治療方法

Also Published As

Publication number Publication date
EP1692111A2 (fr) 2006-08-23
IL175892A0 (en) 2006-10-05
ECSP066635A (es) 2006-10-25
SV2005001973A (es) 2005-11-04
CR8410A (es) 2006-10-04
JP2007516258A (ja) 2007-06-21
CA2547518A1 (fr) 2005-06-30
TW200529845A (en) 2005-09-16
KR20070001922A (ko) 2007-01-04
BRPI0417543A (pt) 2007-03-27
PA8619901A1 (es) 2005-11-25
AU2004298486A1 (en) 2005-06-30
WO2005058834A2 (fr) 2005-06-30
AR047329A1 (es) 2006-01-18
PE20050676A1 (es) 2005-11-02
WO2005058834A3 (fr) 2005-11-17
RU2006124843A (ru) 2008-01-20
US20050131014A1 (en) 2005-06-16
US7576215B2 (en) 2009-08-18
EP2284157A1 (fr) 2011-02-16

Similar Documents

Publication Publication Date Title
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
WO2007079199A3 (fr) Inhibiteurs de métalloprotéases à base de bisamides substitués
NO20060230L (no) Nye aminobenzofenonforbindelser
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2005046603A3 (fr) Composes pyridiniques
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
ATE433447T1 (de) Pyrimiidinverbindungen
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application